---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-046516"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:20:22.877029+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aileron terminates ALRN-6924 Phase 1b trial; cuts workforce to 3; explores strategic alternatives

## Summary
- Phase 1b trial showed Grade 4 neutropenia and alopecia; primary endpoint not met; development of ALRN-6924 terminated.
- Workforce reduced from 9 to 3 employees; severance costs estimated at $1.0-1.1 million, recorded in Q1 2023.
- Company exploring strategic alternatives including M&A, merger, or asset sale; engaged Ladenburg Thalmann as advisor.
- No set timetable for strategic review; no assurance any transaction will occur.

## SEC filing metadata
- accession: 0001193125-23-046516
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312523046516/0001193125-23-046516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312523046516/d433980d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-046516
- JSON: https://secwatch.observer/filing/0001193125-23-046516.json
- Plain text: https://secwatch.observer/filing/0001193125-23-046516.txt

## Key facts
- Restructurings & Charges
  Rein Therapeutics, Inc. announced a restructuring with charges of approximately $1.0 to $1.1 million affecting the Company (reduce the Company’s remaining workforce from nine to three employees).
  - Type: restructuring
  - Charge: approximately $1.0 to $1.1 million
  - Affected area: the Company
  - Headcount: reduce the Company’s remaining workforce from nine to three employees
  source text: nine to three employees. The determination to effect the workforce reduction was made in connection with the Company’s decision, further described below, to terminate its Phase 1b breast cancer trial of ALRN-6924 and further development of ALRN-6924. The workforce reduction is designed to reduce the Company’s operating expenses while the Company explores
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312523046516/0001193125-23-046516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.